PatientsVille.com Logo


Lucentis Medical Research Studies

Up-to-date List of Lucentis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lucentis Medical Research Studies

Rank Status Study
1 Recruiting Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
Condition: Exudative Age-related Macular Degeneration
Interventions: Drug: 4.0 mg iSONEP;   Drug: 0.5 mg iSONEP;   Drug: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea;   Drug: sham injection
Outcome Measures: Mean change in Best Corrected Visual Acuity (BCVA) by ETDRS from Day 0 to Day 120.;   Mean change in central subfield retinal thickness from Day 0 to Day 120.;   Mean change in CNV lesion area from Day 0 to Day 120 as determined by FA.;   Proportion of subjects gaining greater than or equal to 0, 5, 10 and 15 letters on the ETDRS chart.;   Proportion of subjects losing 3 lines or more in ETDRS BCVA.;   Proportion of subjects with ETDRS BCVA of 20/50 or better.;   Proportion of subjects with adverse events.;   Single and multiple-dose pharmacokinetics;   Changes in anti-drug antibodies (ADA) during study and follow-up period
2 Recruiting Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration
Condition: Age Related Macular Degeneration (AMD)
Interventions: Drug: Lucentis;   Drug: PF582
Outcome Measures: To evaluate the safety and tolerability of PF582;   To demonstrate the biosimiliarity between PF582 and Lucentis based on PK;   To demonstrate biosimilarity between PF582 and reference compound (Lucentis)
3 Recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
Outcome Measure: Mean Change in Visual Acuity from Baseline at the Month 12 Visit.
4 Recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
Outcome Measure: Mean Change in Visual Acuity from Baseline at the Month 12 Visit
5 Not yet recruiting Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Condition: Efficacy and Safety of Ranibizumab (Lucentis)
Intervention: Drug: Lucentis Intravitreal injections
Outcome Measures: Mean Change from baseline in Best Correct Visual Acuity (BCVA);   National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) composite score
6 Unknown  Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
Conditions: Macular Degeneration;   Visual Acuity
Intervention: Drug: Ranibizumab
Outcome Measures: Mean change from baseline at 6 months in the best corrected visual acuity (VA) score using an early treatment diabetic retinopathy study eye chart at a starting distance of 4 meters.;   To determine the following: 1:Proportion of subjects who loose fewer than 15 letters from baseline visual acuity at 6 months 2: Proportion of subjects with VA of 20/200 or worse 3: Proportion of subjects with VA of 20/40 or better
7 Recruiting Efficacy Study of Lucentis in the Treatment of Retinoblastoma
Condition: Retinoblastoma
Interventions: Drug: Lucentis, chemotherapy;   Drug: chemotherapy
Outcome Measures: all cause mortality;   Efficacy of Lucentis(intravitreal injection) in the Treatment of Retinoblastoma
8 Not yet recruiting Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
Condition: Wet Age-related Macular Degeneration
Interventions: Drug: Bevacizumab;   Drug: Ranibizumab
Outcome Measures: • Proportion of patients losing fewer than 15 letters on EDTRS chart at month 12;   • Frequency of ocular and systemic adverse events (AE) and serious adverse events (SAE) that are related, in Investigator's opinion, to AMD therapy;   • Frequency of AE and SAE with toxicity level of 3-4 that are related, in Investigator's opinion, to AMD therapy;   • Number of cases of early withdrawal from the study caused by AE or SAE;   • Number of patients who have binding and neutralizing antibodies to BCD-021/Lucentis in serum at screening and month 12;   • The mean titer of binding and neutralizing antibodies to BCD-021/Lucentis in serum at screening and month 12;   • Mean change in VA score, measured on the EDTRS scale at month 12;   • Average number of injections and time before re-injection;   • Lesion size at month 6 and month 12 (by angiography);   • Lesion leakage at month 6 and month 12;   • Change in fluid and foveal thickness on OCT during the study;   • Retinal sensitivity measured by microperimetry at screening, at month 6 and month 12;   • Timing of visual improvement after initiation of therapy
9 Unknown  Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
Conditions: Diabetic Retinopathy;   Macular Edema
Intervention: Drug: Ranibizumab
Outcome Measures: Mean change in Early Treatment for Diabetic Retinopathy Study (ETDRS) eye chart vision.;   Mean number of injections.;   Mean change in spectral domain optical coherence tomography (SD-OCT) central foveal thickness (CFT).;   Percentage of patients with best corrected visual acuity (BCVA) Snellen-equivalent of 20/40 or better.;   Percentage of patients anatomically "dry.";   Number of participants with adverse events as a measure of safety and tolerability.
10 Unknown  Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema
Condition: Uveitic Cystoid Macular Edema
Intervention: Drug: ranibizumab
Outcome Measures: Determine whether patients who receive intravitreal ranibizumab according to the study schedule have improved vision as measured by ETDRS at 4 meters.;   The mean change in BCVA (assessed by the ETDRS chart at 4 meters) from baseline at 12 months will be computed with a t-test.;   The percentage of patients with 15 letters (3 lines) of visual acuity improvement at 30, 60, 90, 120 days, and 12 months.;   The mean change in foveal retinal thickness from baseline at 7 days, and at 30, 60, 90, 120 days, and 12 months will be computed using a t-test.;   The incidence of ocular and non-ocular adverse events will be evaluated through month 24.
11 Recruiting Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
Condition: Retinal Vein Occlusion
Interventions: Drug: Dexamethasone intravitreal implant;   Drug: Monthly Ranibizumab
Outcome Measures: Best Corrected Visual Acuity;   Foveal Thickness
12 Unknown  Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
Condition: Ocular Histoplasmosis Syndrome
Intervention: Drug: ranibizumab
Outcome Measures: incidence and severity of ocular adverse events as identified by eye examination;   incidence and severity of other adverse events as identified by physical examination, subject reporting, and changes in vital signs;   mean change in visual acuity;   mean change in central foveal thickness and total macular volume as obtained by ocular coherence tomography;   change in fluorescein angiographic outcomes;   mean number of injections
13 Recruiting Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis
Condition: Proliferative Diabetic Retinopathy (PDR)
Intervention: Other: Injection of Avastin / Lucentis, sampling aqueous humour
Outcome Measures: The primary outcome will be the change in global levels of intraocular inflammatory cytokines in the aqueous humour of patients with Proliferative Diabetic Retinopathy.;   Secondary outcomes include the change in angiogenic cytokine levels.;   Secondary outcome measure considers intraoperative complications during vitrectomy.
14 Recruiting Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Conditions: Age-Related Macular Degeneration;   Neovascularization, Choroidal
Interventions: Drug: Intravitreal dexamethasone and intravitreal ranibizumab;   Drug: Intravitreal ranibizumab
Outcome Measures: • Central visual function.;   • Changes of intraretinal morphologies (central retinal thickness).;   • Measurement of levels of proteins in the ocular fluid.;   • Perfusion of the neovascular net (FLA and ICG).;   • Chorioretinal perfusion (ICG).;   • Retinal sensitivity (mfERG, Nidek MP-1 microperimetry)
15 Unknown  The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema
Conditions: Uveitis Related Cystoid Macular Edema;   Steroid-induced Glaucoma - Borderline
Intervention: Drug: Ranibizumab
Outcome Measures: The number of patients in whom, by consensus, no further treatment is required.;   Change in CRT as measured by Spectralis spectral domain OCT.;   Functional vision changes based on self-reported quality of life measures (including acceptability of 4 weekly intravitreal therapy).;   The proportion of subjects gaining >10 and >15 letters.;   Change in contrast sensitivity.;   Change in BCVA.;   The proportion of subjects with loss of >15 letters and >30 letters.;   Change in retinal sensitivity on microperimetry.;   Change in reading speed.;   Evidence of improvement in PERG or mfERG.;   Maintenance of the foveal avascular zone.;   Absence of toxicity on Electrophysiological testing / microperimetry / autofluorescence.;   Incidence and severity of ocular adverse events.;   Incidence and severity of non ocular adverse events.
16 Not yet recruiting Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis
Condition: Degeneration of Macula and Posterior Pole
Intervention: Biological: ranibizumab
Outcome Measure:
17 Recruiting Targeted Laser With Lucentis 0.5mg Verses L Lucentis 0.5mg Monotherapy for Ischemic Central Vein, Hemi Retinal Vein Occlusion and Branch Retinal Vein Occlusion
Condition: Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions: Drug: 0.5mg Ranibizumab;   Procedure: Targeted Pan Retinal Photocoagulation
Outcome Measures: Total number of intravitreal injections in a 12 month period;   Visual Acuity;   Retinal Ischemia;   Foveal Avascular Zone;   Adverse Events;   Neovascularization of the Iris, Optic Nerve and Elsewhere;   Central Foveal Outcome;   Aqueous VEG F Levels;   Visual Field
18 Not yet recruiting Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing
Condition: Persistent Diabetic Macular Edema
Intervention: Drug: ranibizumab
Outcome Measure: mean change in optical coherence topography central subfield thickness at 12 weeks and 24 weeks after randomization
19 Unknown  Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study
Condition: Diabetic Macular Edema
Interventions: Drug: Ranibizumab;   Drug: ranibizumab
Outcome Measures: Adverse events;   Visual acuity;   Anatomic Retinal changes
20 Recruiting OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
Condition: Wet Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: OZURDEX
Outcome Measures: Gains in visual acuity;   Changes in intraocular pressure;   Rates of re-treatment;   Rate of vision loss;   Rate of cataract progression;   Changes in choroid vessel activity in lesion growth and activity at choroid

These studies may lead to new treatments and are adding insight into Lucentis etiology and treatment.

A major focus of Lucentis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Lucentis